MiNK Therapeutics GAAP EPS of -$0.65 beats by $0.20
Source: SeekingAlpha
2025-11-14 07:32:31 ET
More on MiNK Therapeutics
- Seeking Alpha’s Quant Rating on MiNK Therapeutics
- Historical earnings data for MiNK Therapeutics
- Financial information for MiNK Therapeutics
Read the full article on Seeking Alpha
For further details see:
MiNK Therapeutics GAAP EPS of -$0.65 beats by $0.20
MiNK Therapeutics Inc.
NASDAQ: INKT
INKT Trading
1.44% G/L:
$10.59 Last:
3,535 Volume:
$10.23 Open:
INKT Latest News
February 03, 2026 09:30:00 pm
MiNK Therapeutics Presents New Data of allo-iNKT Cell Therapy as a Potential Disease-Modifying Approach in Idiopathic Pulmonary Fibrosis at Keystone Symposia
January 08, 2026 12:00:00 pm
MiNK Therapeutics and University of Wisconsin-Madison Announce Phase 1 Clinical Trial of Allo-iNKT Cell Therapy (AgenT-797) to Evaluate Prevention of Graft-Versus-Host Disease
INKT Stock Data
$94,552,132
3,709,418
0.69%
9
N/A
Biotechnology & Life Sciences
Healthcare
US
New York
